bs-7343R [Primary Antibody]
RANK Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: RANK

Immunogen Range: 101-200/616


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human RANK

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.

Background:

CD265 is a member of the tumor necrosis factor receptor (TNFR) family. Human and murine CD265 share 81% amino acid identity in their extracellular domains. CD265 is widely expressed, with highest levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. CD265 is also expressed in dendritic cells. RANK and RANK ligand (RANKL) are important regulators of interactions between T cells and dendritic cells. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Multiple tumor necrosis factor receptor-associated factors (TRAFs) are involved in the signaling of CD265. TRANCE (TNF-related activation-induced cytokines, also known as RANK ligand, osteoprotegerin ligand and osteoclast differentiation factor) is the ligand for CD265. The biological functions mediated by RANK include activation of NFkappaB and cjun N-terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis and lymph node organogenesis. The soluble form of CD265 is able to block TRANCE induced biological activity. The binding of anti-CD265 to cell surface CD265 triggers signal transduction and induces CD265 mediated bioactivity.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)

Predicted Molecular Weight: 63


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Sheep
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Qinyu Ma. et al. Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling. Bone Res. 2021 Jan;9(1):1-12Read more>>
  • Xiaoxiao Liu. et al. Targeting TSP-1 decreased periodontitis by attenuating extracellular matrix degradation and alveolar bone destruction. Int Immunopharmacol. 2021 Jul;96:107618Read more>>
VALIDATION IMAGES

Paraformaldehyde-fixed, paraffin embedded mouse brain tissue; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37°C for 20min; Antibody incubation with Rabbit Anti-RANK Polyclonal Antibody, Unconjugated (bs-7343R) at 1:400 overnight at 4°C, followed by a conjugated secondary and DAB staining


Paraformaldehyde-fixed, paraffin embedded rat skeletal muscle tissue; Antigen retrieval by boiling in sodium citrate buffer(pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37°C for 20min; Antibody incubation with Rabbit Anti-RANK Polyclonal Antibody, Unconjugated (bs-7343R) at 1:400 overnight at 4°C, followed by a conjugated secondary and DAB staining


Lane 1: Recombinant human RANK protein, C-His (HEK293)(bs-43608P) probed with RANK Polyclonal Antibody, Unconjugated (bs-7343R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.